During the last session, Cogent Biosciences Inc. (NASDAQ:COGT)’s traded shares were 1.51 million, with the beta value of the company hitting 2.10. At the end of the trading day, the stock’s price was $11.99, reflecting an intraday gain of 12.58% or $1.34. The 52-week high for the COGT share is $12.08, that puts it down -0.75 from that peak though still a striking 68.39% gain since the share price plummeted to a 52-week low of $3.79. The company’s market capitalization is $1.06B, and the average intraday trading volume over the past 10 days was 0.6 million shares, and the average trade volume was 2.95 million shares over the past three months.
Cogent Biosciences Inc. (COGT) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.40. COGT has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.65.
Cogent Biosciences Inc. (NASDAQ:COGT) trade information
Cogent Biosciences Inc. (COGT) registered a 12.58% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.58% in intraday trading to $11.99 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 6.29%, and it has moved by 10.00% in 30 days. Based on these gigs, the overall price performance for the year is 81.39%. The short interest in Cogent Biosciences Inc. (NASDAQ:COGT) is 5.68 million shares and it means that shorts have 4.5 day(s) to cover.
The consensus price target of analysts on Wall Street is $17.86, which implies an increase of 32.87% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $23.00 respectively. As a result, COGT is trading at a discount of -91.83% off the target high and -25.1% off the low.
Cogent Biosciences Inc. (COGT) estimates and forecasts
Statistics show that Cogent Biosciences Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Cogent Biosciences Inc. (COGT) shares have gone up 71.04% during the last six months, with a year-to-date growth rate less than the industry average at -33.69% against 1.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -51.20% this quarter and then drop -22.90% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.40%. While earnings are projected to return 88.50% in 2022.
Cogent Biosciences Inc. is due to release its next quarterly earnings between March 14 and March 18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cogent Biosciences Inc. (NASDAQ:COGT)’s Major holders
Cogent Biosciences Inc. insiders own 0.01% of total outstanding shares while institutional holders control 63.86%, with the float percentage being 63.86%. Eventide Asset Management LLC is the largest shareholder of the company, while 136 institutions own stock in it. As of Mar 30, 2022, the company held over 3.9 million shares (or 8.51% of all shares), a total value of $29.21 million in shares.
The next largest institutional holding, with 3.5 million shares, is of Commodore Capital, LP’s that is approximately 7.64% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $26.22 million.
Also, the Mutual Funds coming in first place with the largest holdings of Cogent Biosciences Inc. (COGT) shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and iShares Russell 2000 ETF. Data provided on Mar 30, 2022 indicates that Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund owns about 3.9 million shares. This amounts to just over 8.51 percent of the company’s overall shares, with a $29.21 million market value. The same data shows that the other fund manager holds slightly less at 1.0 million, or about 2.18% of the stock, which is worth about $9.01 million.